Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Colorcon

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Litigation Details for Forest Laboratories Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Forest Laboratories Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-01-31
Court District Court, D. Delaware Date Terminated 2016-07-26
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties ADAMAS PHARMACEUTICALS INC.; FOREST LABORATORIES HOLDINGS LTD.; FOREST LABORATORIES INC.; MERZ PHARMA GMBH & CO. KGAA; MERZ PHARMACEUTICALS GMBH; SUN PHARMA GLOBAL FZE; SUN PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA INC.; WOCKHARDT BIO AG; WOCKHARDT LTD.; WOCKHARDT USA LLC
Patents 5,061,703; 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; 8,598,233
Attorneys Alexandra J. Olson; Bindu Ann George Palapura; Christopher A. Pinahs; David Ellis Moore; Jack B. Blumenfeld; Jeffer Ali; Jeffrey D. Blake; Jeffrey S. Ward; Jennell Bilek; John C. Phillips , Jr.; Kenneth Laurence Dorsney; Mark D. Schuman; Maryellen Noreika; Richard L. Horwitz
Link to Docket External link to docket
Small Molecule Drugs cited in Forest Laboratories Inc. v. Teva Pharmaceuticals USA Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Forest Laboratories Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-01-31 1 of the following patents by each of the Defendants: United States Patent Nos. 5,061,703, as corrected and…#39;703 patent, the '009 patent, the '209 patent, the '708 patent, the '379 patent, the …#39;009 patent, the '209 patent, the '708 patent, the '379 patent, the '752 patent, and …#39;009 patent, the '209 patent, the '708 patent, the '379 patent, the '752 patent, and …#39;009 patent, the '209 patent, the '708 patent, the '379 patent, the '752 patent, and External link to document
2015-05-14 103 infringement of U.S. Patent Nos. 8,039,009 (“the ‘009 patent”); 8,168,209 (“the ‘209 Patent”); 8,173,708 (“…‘009 Patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, and…‘009 Patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, and…‘009 Patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, and…‘009 patent, the ‘209 Patent, the ‘708 Patent, the ‘379 Patent, the ‘752 Patent, the ‘085 Patent, and External link to document
2015-12-08 189 Noninfringement of Claims 13 and 14 of U.S. Patent No. 8,168,209 [Highly Confidential-Subject to Protective…2014 26 July 2016 1:14-cv-00121-LPS Patent None District Court, D. Delaware External link to document
2016-01-05 194 5,061 ,703 ("' 703 patent") (collectively, the "patents-in-suit"). … There are eight patents-in-suit: U.S. Patent Nos. 8,168,209 ("'209 patent"), 8,173,708…; 708 patent"), 8,283,379 ('"379 patent"), 8,329,752 ("' 752 patent"… "Went patents"); as well as U.S. Patent Nos. 8,039,009 ("' 009 patent") and 5,061…; 209 patent, claims 1, 6, 10, and 15 of the ' 708 patent, claim 1 of the '3 79 patent, claims External link to document
2014-01-31 3 Expiration of Patent: 8,039,009 03/24/2029. 8,168,209.8,173,708. 8,283,379. 8,362,085. 8,598,233 11/22/2025… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2014 26 July 2016 1:14-cv-00121-LPS Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKinsey
Johnson and Johnson
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.